Pfizer Inc. PFE shares are sitting right below key technical resistance at $30.31.
Is this a short-seller's dream set-up, or is it a stock that's gathering steam for a major breakout?
What The Bulls See...
• A healthy, Treasury-beating dividend yield of 3.50 percent
• An enterprise value of $192.25 billion that edges out the market capitalization of $191.49 billion
• A price-to-book ratio of 2.48
• A price-to-sales ratio of 3.79
• Net profit margins of over 20 percent that spin off over $14 billion in annual levered free cash flow
• Healthy balance sheet metrics, including a current ratio of over 2.8 and a debt-to-equity ratio of 47.4 percent
What The Bears See...
• A relatively expensive price-to-earnings ratio near 15 times next year's consensus estimates when compared with estimated 2015 revenue and earnings growth of -1.9 percent and 1.4 percent, respectively
• A stock that's sitting below key resistance and is still overbought in the short-term
The Technical Take
Pfizer shares, technically speaking, could remain in a bearish technical posture unless it can manage to break and close above its downtrend-line resistance of $30.31.
The stock is overbought at this critical technical juncture, so a breakout may not be in the cards.
A failure and bearish reversal at resistance could mean a move back down to the August and October lows between $27 and $29. A breakout, on the other hand, would open up the door to more upside -- perhaps between $30.84 and $31.31.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.